Key Dates

 

Related Announcements

• September 6, 2023 - Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STTR). See Notice NOT-EY-23-009.

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this Notice is to inform potential applicants that the NIBIB is participating, effective immediately, in NOT-EY-23-009, “Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STTR)."

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to transform through engineering the understanding of disease and its prevention, detection, diagnosis, and treatment. The Small Business Program at the NIBIB contributes to the mission of the institute by supporting innovative technologies through various stages of commercial research and development. The NIBIB welcomes SBIR and STTR applications from small businesses proposing ideas relevant to its scientific program areas. Please review NIBIB’s Small Business Program Description for additional details and contact program staff if you have questions about which institute(s) would be the best fit for your technology.

NIBIB interests include the development and integration of advanced bioengineering, sensing, imaging, and computational technologies for the improvement of human health and medical care. An application is not within the NIBIB mission if its principal focus is the development of a technology with the goal of understanding basic biological functions  or pathological mechanisms. Additionally, NIBIB only supports projects developing platform technologies that are applicable to a broad spectrum of disorders and diseases. However, applicants may propose research that utilizes only a single tissue, organ, or physiological condition as a model system to facilitate the development and translation of what is expected to be a more broadly applicable enabling technology.

Examples of research of interest to NIBIB include, but are not limited to:

• Development of novel quantum imaging and sensing technologies to support clinical decisions.
• Advanced quantum AI/ML algorithms, modeling, or simulation technologies
• Quantum-based  point-of-care technologies for the clinical or hospital setting.
• Wearables and portable devices leveraging quantum technology for continuous monitoring, diagnostic or therapeutic purposes

For this NOSI, if an application proposes a clinical trial, NIBIB funding of clinical trials will be in accordance with NOT-EB-21-005 "NIBIB Guidance for Support of Clinical Trial Applications." Briefly, NIBIB will only support mission-focused (see NIBIB's program areas) early-stage clinical trial applications, i.e., feasibility, Phase I, first-in-human, safety, or other small clinical trials, that inform early-stage technology development. NIBIB will not support applications proposing pivotal, Phase II, III, IV, or trials in which the primary outcome is efficacy, effectiveness, or a post-market concern. Also, mechanistic trials are not supported unless the primary focus of the project is on technology development.)

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)
Kari Ashmont, Ph.D. 
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Email:nibib-sbir@mail.nih.gov

Afrouz Anderson, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-435-0513 
Email:afrouz.anderson@nih.gov